Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes

Cited by (793)

Items 201–300 of 793

1. Assessment of Target Organ Damage in the Evaluation and Follow‐Up of Hypertensive Patients: Where Do We Stand?
   Gadi Shlomai, Guido M. Grassi, Ehud Grossman, Giuseppe Mancia · 2013 · Journal of Clinical Hypertension
2. Study design of DIACORE (DIAbetes COhoRtE) – a cohort study of patients with diabetes mellitus type 2
   L. Dorhofer, Alexander Lammert, Vera Krane, Mathias Gorski, Bernhard Banas, Christoph Wanner, Bernhard Karl Krämer, Iris M. Heid, Carsten A. Böger, for the DIACORE Study Group · 2013 · BMC Medical Genetics
3. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes
   Michelle J. Pena, Dick de Zeeuw, Harald Mischak, Joachim Jankowski, Rainer W. Oberbauer, Wolfgang Woloszczuk, Jacqueline Benner, Guido Dallmann, Bernd Mayer, Gert J. Mayer et al. · 2015 · Nephrology Dialysis Transplantation
4. Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes—Network meta-analysis of randomized trials
   Luciana Reck Remonti, Sofia Dias, Cristiane Bauermann Leitão, Caroline Kaercher Kramer, Lucas Pires Klassmann, Nicky J. Welton, Anthony E. Ades, Jorge Luiz Gross · 2016 · Journal of Diabetes and its Complications
5. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
   Tomoaki Takata, Hajime Isomoto · 2021 · International Journal of Molecular Sciences
6. Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis
   Analina R. da Silva, Rodrigo A. Fraga‐Silva, Nikolaos Stergiopulos, Fabrizio Montecucco, François Mach · 2015 · European Journal of Clinical Investigation
7. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy
   Dan Ding, Yimei Du, Zhihua Qiu, Sen Yan, Fen Chen, Min Wang, Shijun Yang, Yanzhao Zhou, Xiajun Hu, Yihuan Deng et al. · 2015 · Journal of Molecular Medicine
8. Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders
   Ludovít Paulis, Sébastien Foulquier, Pawel Namsolleck, Chiara Recarti, U. Muscha Steckelings, Thomas Unger · 2015 · Drugs
9. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice–potential role of the ACE2/AT2R/Mas axis
   Glaucia Elena Callera, Tayze T. Antunes, José Wilson do Nascimento Corrêa, Danielle Moorman, Alex A. Gutsol, Ying He, Aurélie Nguyen Dinh Cat, Ana María Briones, Augusto C. I. Montezano, Kevin D. Burns et al. · 2016 · Bioscience Reports
10. Microalbuminuria and cardiorenal risk: old and new evidence in different populations
    Diego Francisco Márquez, Gema Ruiz‐Hurtado, J. Segura, Luis Miguel Ruilope · 2019 · F1000Research
11. Hypertensive kidney disease: true epidemic or rare disease?
    Tomasz P. Stompór, Agnieszka Perkowska‐Ptasińska · 2020 · Polskie Archiwum Medycyny Wewnętrznej
12. Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
    Qianqian Yang, Ruizhi Zheng, Siyu Wang, Jiamin Zhu, Mian Li, Tiange Wang, Zhiyun Zhao, Min Xu, Jieli Lu, Yuhong Chen et al. · 2023 · Hypertension
13. Novel Urinary Biomarkers in Early Diabetic Kidney Disease
    Atsuko Kamijo‐Ikemori, Takeshi Sugaya, Kenjiro Kimura · 2014 · Current Diabetes Reports
14. Angiotensin II increases glomerular permeability by β-arrestin mediated nephrin endocytosis
    Eva Königshausen, Ulf M. Zierhut, Martin Ruetze, Sebastian Alexander Potthoff, Johannes Stegbauer, Magdalena Woznowski, Ivo Quack, Lars Christian Rump, Lorenz K. Sellin · 2016 · Scientific Reports
15. Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate—Free Radical Scavenger and Growth Factor Inhibition
    Hermann G. Haller, Linong Ji, Klaus Stahl, Anna Bertram, Jan Menne · 2017 · BioMed Research International
16. SGLT2 inhibition to address the unmet needs in diabetic nephropathy
    Federica Barutta, Sara Bernardi, Giuseppe Gargiulo, Marilena Durazzo, Gabriella Gruden · 2019 · Diabetes/Metabolism Research and Reviews
17. Nonproteinuric Diabetic Nephropathy
    Jamie P. Dwyer, Julia Breyer Lewis · 2012 · Medical Clinics of North America
18. Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: A population-based study
    María Esteve, Rocío Temiño, Anna Carrasco, Lissette Batista, Adolfo del Val, Michel Blé, Santos Santaolaria, Javier Molina‐Infante, Germán Soriano, Sandra Agudo et al. · 2015 · Digestive and Liver Disease
19. What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?
    Samir G. Mallat · 2012 · Cardiovascular Diabetology
20. Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
    Rosaria Vincenza Giglio, Angelo Maria Patti, Ali Abbas Rizvi, Anca Pantea Stoian, Marcello Ciaccio, Νικόλαος Παπάνας, Andrej Janež, Alper Sönmez, Maciej Banach, Amirhossein Sahebkar et al. · 2023 · Biomedicines
21. Diabetic Kidney Disease and the Cardiorenal Syndrome
    Ankur Jindal, Mariana Garcia‐Touza, Nidhi Jindal, Adam T. Whaley‐Connell, James R. Sowers · 2013 · Endocrinology and Metabolism Clinics of North America
22. Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy
    Tatsuhiko Azegami, Hiroyuki Sasamura, Kaori Hayashi, Hiroshi Itoh · 2011 · Hypertension Research
23. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension
    Pantelis A. Sarafidis, Roland Erich Schmieder, Michel Burnier, Alexandre Persu, Andrzej Januszewicz, Jean‐Michel Halimi, Mustafa Arıcı, Alberto Ortíz, Christoph Wanner, Giuseppe Mancia et al. · 2024 · Nephrology Dialysis Transplantation
24. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus
    Xiaodan lv, Yingshi Zhang, Yixuan Niu, Qi Song, Qingchun Zhao · 2018 · Medicine
25. Chronic kidney disease as a cardiovascular risk factor
    Rafael Carmena, Juan Francisco Ascaso, Josep Redón · 2020 · Journal of Hypertension
26. Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?
    Frank Thomas Ruschitzka, S. Taddei · 2012 · European Heart Journal
27. Effect of renin–angiotensin–aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis
    Ionuţ Nistor, Johan DE SUTTER, Christiane Drechsler, David J.A. Goldsmith, María José Soler, Charles Tomson, Andrzej Więcek, Mihaela‐Dora Donciu, Davide Bolignano, Wim Van Biesen et al. · 2017 · Nephrology Dialysis Transplantation
28. Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
    Jin Wook Lee, Hyun-Oh Gu, Yunshin Jung, YunJae Jung, Seung‐Yong Seo, Jeong Hee Hong, In‐Sun Hong, Dae Ho Lee, Ok‐Hee Kim, Byung‐Chul Oh · 2023 · Experimental & Molecular Medicine
29. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
    Csaba Farsang · 2011 · Vascular Health and Risk Management
30. New Insight into the Molecular Drug Target of Diabetic Nephropathy
    Vivian Soetikno, Wawaimuli Arozal, Melva Louisa, Rianto Setiabudy · 2014 · International Journal of Endocrinology
31. Evidence‐Based Hypertension Treatment in Patients With Diabetes
    Mariana Garcia‐Touza, James R. Sowers · 2011 · Journal of Clinical Hypertension
32. Effects of dual blockade of the renin–angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT–Hypertension)
    Enyu Imai, Masakazu Haneda, Tetsu Yamasaki, Fumiaki Kobayashi, Atsushi Harada, Sadayoshi Ito, Juliana C.N. Chan, Hirofumi Makino · 2013 · Hypertension Research
33. To RAS or Not to RAS ? The Evidence for and Cautions with Renin‐Angiotensin System Inhibition in Patients with Diabetic Kidney Disease
    Wendy L. St. Peter, Lauren E. Odum, Adam T. Whaley‐Connell · 2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
34. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure — A network meta-analysis
    Fabrizio Ricci, Augusto Filippo Di Castelnuovo, Gianluigi Savarese, Pasquale Perrone Filardi, Raffaele De Caterina · 2016 · International Journal of Cardiology
35. Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
    Michael Johann Koziolek, Gerhard Anton Muller, Gry Helene Dihazi, Klaus Jung, Constanze Altubar, Manuel Wallbach, Ivana Markovic, Dirk Raddatz, Olaf Jahn, Hülya Karaköse et al. · 2020 · Journal of Clinical Medicine
36. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease
    Mai Yanagi, Kouichi Tamura, Tetsuya Fujikawa, Hiromichi Wakui, Tomohiko Kanaoka, Masato Ohsawa, Kengo Azushima, Akinobu Maeda, Hiroyuki Kobori, Satoshi Umemura · 2012 · Hypertension Research
37. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
    Renee E. Garrick · 2011 · Yearbook of Medicine
38. Lysyl oxidases expression and histopathological changes of the diabetic rat nephron
    Jun Chen, Jie Ren, Wings T.Y. Loo, Liang Hao, Min Wang · 2017 · Molecular Medicine Reports
39. Drug Testing for Residual Progression of Diabetic Kidney Disease in Mice Beyond Therapy with Metformin, Ramipril, and Empagliflozin
    Manga Motrapu, Monika Katarzyna Świderska, Irene Mesas Aranda, Julian Aurelio Marschner, Yutian Lei, Laura Martínez Valenzuela, Jia Fu, Kyung Lee, Maria Lucia Angelotti, Giulia Antonelli et al. · 2020 · Journal of the American Society of Nephrology
40. Proximal tubular angiotensinogen in renal biopsy suggests nondipper BP rhythm accompanied by enhanced tubular sodium reabsorption
    Michio Fukuda, Maki Urushihara, Tamaki Wakamatsu, Tadashi Oikawa, Hiroyuki Kobori · 2012 · Journal of Hypertension
41. Characteristics of high‐ and low‐risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
    Nete Tofte, Morten Kofod Lindhardt, Katarina Adamova, Joachim Beige, Joline W. J. Beulens, Andreas L. Birkenfeld, Gemma E. Currie, Christian Delles, Ingo Dimos, Lidmila Francová et al. · 2018 · Diabetic Medicine
42. Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review
    Reinhold Hugo Kreutz, Mattias Brunström, Costas Thomopoulos, Bo Carlberg, Giuseppe Mancia · 2022 · Journal of Hypertension
43. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
    Massimo Volpe, Giuliano Tocci · 2012 · Vascular Health and Risk Management
44. Comparative Effectiveness of Olmesartan and Other Angiotensin Receptor Blockers in Diabetes Mellitus
    Raj S. Padwal, Lin Mu, Mahyar Etminan, Dean T. Eurich · 2014 · Hypertension
45. Novedades en hipertensión arterial y diabetes mellitus
    Alberto Cordero, Lorenzo Fácila, Enrique Galve, Pilar Mazón · 2010 · Revista Española de Cardiología
46. Disparities in Blood Pressure Control Within a Community-Based Provider Network: An Exploratory Analysis
    Robert J. Romanelli, Timothy A. Schiro, Trevor Jukes, Ken S Wong, Denis Y. Ishisaka · 2011 · Annals of Pharmacotherapy
47. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study
    Yayoi Nishida, Yasuo Takahashi, Tomohiro Nakayama, Masayoshi Soma, Satoshi Asai · 2011 · Cardiovascular Diabetology
48. Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement
    Ajitesh Roy, Animesh Maiti, Anirban Sinha, Arjun Baidya, Asish Kumar Basu, Dasarathi Sarkar, Debmalya Sanyal, Dibakar Biswas, Indira Maisnam, Kaushik Pandit et al. · 2020 · Diabetes Therapy
49. Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway
    Yaping Xiao, Jianling Deng, Chunming Li, Xiaobao Gong, Zhenwei Gui, Jieyao Huang, Yaru Zhang, Yan Liu, Xiaoli Ye, Xuegang Li · 2021 · Phytomedicine
50. Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future
    Ritwika Mallik, Tahseen Ahmad Chowdhury · 2022 · Therapeutic Advances in Endocrinology and Metabolism
51. Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives
    Bo Lin, Ying‐Yu Ma, Wang Jun-wei · 2022 · Frontiers in Bioengineering and Biotechnology
52. Clinical Manifestations and Natural History of Diabetic Kidney Disease
    Eberhard Ritz · 2013 · Medical Clinics of North America
53. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure
    Costas Thomopoulos, Gianfranco Parati, Alberto Zanchetti · 2017 · Journal of Hypertension
54. The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy
    Atsuhisa Sato · 2015 · Hypertension Research
55. Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus
    Mattias Brunström, Mats Eliasson, Peter M. Nilsson, Bo Carlberg · 2016 · Journal of Hypertension
56. Management of diabetic kidney disease: where do we stand?: A narrative review
    Devada Sindhu, Gaurav Shekhar Sharma, Damodar R. Kumbala · 2023 · Medicine
57. Treatment and practical considerations of diabetic kidney disease
    Yara Bilen, Allaa Almoushref, Kenda Alkwatli, Omar Osman, Ali Mehdi, Hanny Sawaf · 2023 · Frontiers in Medicine
58. The Pathogenesis and Management of Hypertension in Diabetic Kidney Disease
    Peter Noel Van Buren, Robert D. Toto · 2012 · Medical Clinics of North America
59. Azilsartan: Current Evidence and Perspectives in Management of Hypertension
    Akshyaya Kumar Pradhan, Ashish Tiwari, Rishi Sethi · 2019 · International Journal of Hypertension
60. Prevention of Chronic Kidney Disease and Subsequent Effect on Mortality: A Systematic Review and Meta-Analysis
    Usman Khan, Amit X. Garg, Chirag R. Parikh, Steven G. Coca · 2013 · PLoS ONE
61. Vascular, cardiac and renal target organ damage associated to arterial hypertension: which noninvasive tools for detection?
    Francesca Cortese, Annagrazia Cecere, Anna Maria Cortese, Andrea Andriani, Luigi Truncellito, Federica Valente, Paola Giordano, Marco Matteo Ciccone · 2020 · Journal of Human Hypertension
62. Intraclass Differences Among Antihypertensive Drugs
    Ross D. Feldman, Yasin Hussain, Laura M. Kuyper, Finlay Aleck McAlister, Raj S. Padwal, Sheldon W. Tobe · 2014 · The Annual Review of Pharmacology and Toxicology
63. Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults.
    Pablo Aschner M, Óscar Múñoz, Diana Marcela Girón Cardozo, Olga Milena García, Daniel Gerardo Fernández-Ávila, Luz Ángela Casas, Luisa Fernanda Bohórquez, Clara María Arango Toro, Liliana Carvajal, Doris Ramírez de Peña et al. · 2016 · Europe PMC (PubMed Central)
64. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan
    Stefano Omboni, Massimo Volpe · 2018 · Cardiovascular Therapeutics
65. ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE
    Adrian Liew, Sunita Bavanandan, Narayan Prasad, Muh Geot Wong, Jer Ming Chang, Somchai Eiam‐Ong, Chuan‐Ming Hao, Chiao Yuen Lim, Soo Kun Lim, Kook‐Hwan Oh et al. · 2020 · Nephrology
66. Sex-Related Aspects in Diabetic Kidney Disease—An Update
    Ivonne Loeffler, Nadja Ziller · 2023 · Journal of Clinical Medicine
67. Effects of renin–angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis
    Yoko M. Nakao, Satoshi Teramukai, Sachiko Tanaka, Shinji Yasuno, Akira Fujimoto, Masato Kasahara, Kenji Ueshima, Kazuhiro Nakao, Shiro Hinotsu, Kazuwa Nakao et al. · 2011 · Diabetes Research and Clinical Practice
68. GWAS of Diabetic Nephropathy: Is the GENIE out of the Bottle?
    Carsten A. Böger, John R. Sedor · 2012 · PLoS Genetics
69. Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge
    In Suck Choi, Ie Byung Park, Ki‐Young Lee, Tae Hoon Ahn, Ju Han Kim, Youngkeun Ahn, Sung-Chull Chae, Hyo-Soo Kim, Young‐Jo Kim, Myeong‐Chan Cho et al. · 2018 · Journal of Cardiovascular Pharmacology and Therapeutics
70. Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension
    Felix Mahfoud, Christian Ukena, Janine Pöss, Peter Bramlage, Massimo Volpe, Martin Thoenes, Roland Erich Schmieder, Michael Böhm · 2012 · Clinical Research in Cardiology
71. Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension
    Flávio Danni Fuchs, Luíz Cesar Nazário Scala, José Fernando Vilela-Martin, Renato Gorga Bandeira de Mello, Francisca Mosele, Paul Kieran Whelton, Carlos Eduardo Poli‐de‐Figueiredo, Paulo Ricardo de Alencastro, Ricardo Pereira e Silva, Miguel Gus et al. · 2016 · Journal of Hypertension
72. Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
    Xiaoying Gu, Su Zhang, Ti Zhang · 2021 · Cells
73. How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE ‐ MS
    Harald Mischak · 2012 · PROTEOMICS - CLINICAL APPLICATIONS
74. The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’—implications for pre-clinical research and drug testing
    Lidia Anguiano, Yutian Lei, Satish Kumar Devarapu, Hans‐Joachim Anders · 2017 · Nephrology Dialysis Transplantation
75. A non-laboratory-based risk score for predicting diabetic kidney disease in Chinese patients with type 2 diabetes
    Mian Wu, Junxi Lu, Lei Zhang, Fengjing Liu, Si Chen, Ying Han, Fangya Zhao, Kaifeng Guo, Yuqian Bao, Haibing Chen et al. · 2017 · Oncotarget
76. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
    Giuseppe Mancia, Guido M. Grassi · 2018 · Diabetologia
77. ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation
    Mohamed Ahmed Sobhy, Adel Eletriby, Hany Ibrahim Ragy, Hossam Kandil, Mohamed Ayman Saleh, Nabil Mahmoud Farag, Ramez R. Guindy, Ahmed Bendary, Ahmed El Mahmoudy Nayel, Ahmed Shawky et al. · 2024 · Cardiology and Therapy
78. Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: apost hocanalysis (ORIENT-blood pressure)
    Enyu Imai, Sadayoshi Ito, Masakazu Haneda, Atsushi Harada, Fumiaki Kobayashi, Tetsu Yamasaki, Hirofumi Makino, Juliana C.N. Chan · 2015 · Nephrology Dialysis Transplantation
79. Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes
    Qingrong Pan, Yuan Xu, Ning Yang, Xia Gao, Jia Liu, Wenying Yang, Guang Wang · 2016 · Medicine
80. Change in Proteinuria or Albuminuria as a Surrogate for Cardiovascular and Other Major Clinical Outcomes: A Systematic Review and Meta-analysis
    Tyrone G. Harrison, Helen Tam‐Tham, Brenda R. Hemmelgarn, Meghan Jessica Elliott, Matthew Thomas James, Paul Everett Ronksley, Min Jun · 2018 · Canadian Journal of Cardiology
81. Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
    Namrata Singhania, Saurabh K. Bansal, Shreya Mohandas, Divya Pramod Nimmatoori, Abutaleb Ahsan Ejaz, Girish Singhania · 2020 · Drugs in Context
82. Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression
    Pantelis A. Sarafidis, Luis Miguel Ruilope · 2012 · Journal of the Renin-Angiotensin-Aldosterone System
83. Angiotensinogen Expression Is Enhanced in the Progression of Glomerular Disease
    Maki Urushihara, Hiroyuki Kobori · 2011 · International Journal of Clinical Medicine
84. Obesity, Renin-Angiotensin System Blockade and Risk of Adverse Renal Outcomes: A Population-Based Cohort Study
    Jordana B. Cohen, Alisa J. Stephens‐Shields, Michelle Denburg, Amanda Hyre Anderson, Raymond R. Townsend, Peter Philip Reese · 2016 · American Journal of Nephrology
85. Predictors for the development of microalbuminuria and interaction with renal function
    Christos Chatzikyrkou, Jan Menne, Joseph L. Izzo, Giancarlo C. Viberti, Ton J. Rabelink, Luis Miguel Ruilope, Christian Rump, Peter Rene Mertens, Hermann G. Haller · 2017 · Journal of Hypertension
86. Switching from low‐dose thiazide diuretics to sodium–glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension
    Tomohiko Kimura, Junpei Sanada, Masashi Shimoda, Hidenori Hirukawa, Yoshiro Fushimi, Momoyo Nishioka, Tomoe Kinoshita, Seizo Okauchi, Atsushi Obata, Kenji Kohara et al. · 2017 · Journal of Diabetes Investigation
87. Deciphering the Efficacy and Mechanisms of Chinese Herbal Medicine for Diabetic Kidney Disease by Integrating Web-Based Biochemical Databases and Real-World Clinical Data: Retrospective Cohort Study
    Chien-Wei Wu, Hsing‐Yu Chen, Ching-Wei Yang, Yu‐Chun Chen · 2021 · JMIR Medical Informatics
88. Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best?
    Eva Vivian, Chelsea Mannebach · 2013 · Drugs in Context
89. Plasma Molecular Signatures in Hypertensive Patients With Renin–Angiotensin System Suppression
    Montserrat Baldan Martin, Laura Mouriño-Álvarez, Laura Gonzalez‐Calero, Rafael Moreno‐Luna, Tamara Sastre-Oliva, Gema Ruiz‐Hurtado, J. Segura, Juan Antonio López, Jesús Vázquez, Fernando Vivanco et al. · 2016 · Hypertension
90. The Validity of Drug Effects on Proteinuria, Albuminuria, Serum Creatinine, and Estimated GFR as Surrogate End Points for ESKD: A Systematic Review
    Suetonia C. Palmer, Marinella Ruospo, Armando M Teixeira-Pinto, Jonathan C. Craig, Petra Macaskill, Giovanni FM Strippoli · 2018 · American Journal of Kidney Diseases
91. Mineralcorticoid receptor blockers in chronic kidney disease
    Sara Erraez, Manuel López-Mesa, Pablo Gómez-Fernández · 2021 · Nefrología (English Edition)
92. Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressure–Lowering Treatment on Clinical Outcomes
    Mattias Brunström, Costas Thomopoulos, Bo Carlberg, Reinhold Kreutz, Giuseppe Mancia · 2021 · Hypertension
93. The Role of Irbesartan in the Treatment of Patients with Hypertension
    Claudio Borghi, Arrigo F.G. Cicero · 2012 · High Blood Pressure & Cardiovascular Prevention
94. Rate of blood pressure control and antihypertensive treatment approaches in diabetic patients with hypertension
    Nihan Kahya Eren · 2014 · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
95. Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study
    Wei‐Fan Hsu, Shi-Hang Yu, Jaw-Town Lin, Jaw‐Ching Wu, Ming‐Chih Hou, Yi‐Hsiang Huang, Chun‐Ying Wu, Cheng‐Yuan Peng · 2019 · Gastroenterology Research and Practice
96. The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening
    Frederick C. F. Otieno, Elijah Nyainda Ogola, Mercy W Kimando, Kenn Mutai · 2020 · BMC Nephrology
97. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
    Rosalie Annemien Scholtes, Michaël J.B. van Baar, Megan D. Kok, Petter Bjornstad, David Z.I. Cherney, Jaap A. Joles, Daniël H. van Raalte · 2020 · Nephrology
98. The effect of renin–angiotensin–aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials
    Noor Alsalemi, Cheryl A Sadowski, Naoual Elftouh, Maudeline Louis, Kelley Kilpatrick, Sherilyn K. D. Houle, Jean‐Philippe Lafrance · 2022 · BMC Nephrology
99. Traditional Chinese medicine for the treatment of diabetic kidney disease: A study-level pooled analysis of 44 randomized controlled trials
    Xuele Liu, Minyao Ge, Xinyu Zhai, Yang Xiao, Yaheng Zhang, Ziling Xu, Zhiguang Zhou, Zubing Mei, Xuejun Yang · 2022 · Frontiers in Pharmacology
100. Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes
     Gianpaolo Reboldi, Giorgio Gentile, Valeria Maria Manfreda, Fabio Angeli, Paolo Verdecchia · 2011 · Current Cardiology Reports